Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

A snake venom enzyme shows anti-SARS-CoV-2 activity in vitro

A new study reports the virucidal and fusion-inhibiting attributes of snake venom against the COVID-19 agent SARS-CoV-2.

14 Jan 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Influenza drug enisamium a potential COVID-19 treatment

Researchers in Europe and the United States have demonstrated the potential of the influenza drug enisamium as a treatment for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Jan 2021

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

Researchers at Columbia University have provided important insights into features of viral binding and recognition within a class of potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Jan 2021

How has the UK-derived SARS-CoV-2 mutant strain spread internationally?

Researchers analyzed Facebook-based mobility data and found that travelers from UK may have spread the new SARS-CoV-2 strain that originated in the UK to at least 16 countries by the beginning of December 2020.

13 Jan 2021

Moderna to develop three new mRNA-based vaccines against HIV, influenza, and the Nipah virus

Morderna has announced plans to develop a range of new mRNA-based vaccines against other viruses, including the influenza virus, human immunodeficiency virus (HIV), and the Nipah virus.

13 Jan 2021

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

Researchers from the University of Cambridge and the Pirbright Institute in the UK have identified key genetic changes in SARS-CoV-2 that may be responsible for the virus’s jump from bats to humans. The team also determined which animals contain cellular receptors that allow the virus to enter cells more effectively, zoning in on potential animals that acted as an intermediary host in facilitating SARS-CoV-2’s zoonosis.

13 Jan 2021

New N501 SARS-CoV-2 mutation may have been circulating in Italy since August 2020

A recent study shows that mutated SARS-CoV-2 strains with a substitution at position 501 might have circulated unnoticed even before the end of September 2020, when the rapid emergence of B.1.1.7 lineage (carrying the N501Y mutation) was initially reported.

13 Jan 2021

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.

13 Jan 2021

Could fenofibrate be an effective antiviral against SARS-CoV-2?

The resurgence of COVID-19 pandemic, caused by the SARS-CoV-2, has led to renewed efforts to find effective antivirals, both newly developed or repurposed drugs. A study reports the efficacy of the cholesterol-reducing drug fenofibrate in reducing infection rates of SARS-CoV-2 in cultured cells.

13 Jan 2021

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.

12 Jan 2021

Intranasal vaccination effectively reduces viral shedding of SARS-CoV-2 in monkeys

A new preprint that appeared on the bioRxiv server reports that intranasal vaccination with the D614G variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus monkeys reduces viral shedding. This is an experiment in non-human primates (NHP), and its extrapolation to humans is unclear as yet.

12 Jan 2021

Structure of SARS-CoV-2 cytoplasmic tail uncovered

The virus's cytosolic tail also interacts with the host cell to promote its entry into the endoplasmic reticulum (ER). A new study appearing on the bioRxiv preprint server elucidates the conformation of this region of the virus, which will help understand how its form is related to its function in viral entry.

12 Jan 2021

Effect of mutations in the South African SARS-CoV-2 variant on transmission and neutralization

One such strain is the South African 501.V2 and UK B1.1.7 strains, which have been isolated from many countries and seem to spread faster than the ancestral strain. A preprint that recently appeared on the bioRxiv server reports the computational structure of this strain and the possible effect of the mutations on infectivity and neutralization.

12 Jan 2021

Bleeding disorder linked to poor clinical outcomes in COVID-19 patients

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the pathogen responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic. Approximately 20-55% of hospitalized COVID-19 patients are reported to have deranged hemostatic laboratory parameters, which suggests coagulopathy.

12 Jan 2021

Antigenic "supersite" could improve design of COVID-19 vaccines

Researchers in the United States have defined an antigenic “supersite” within the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have important implications for the design of vaccines to protect against coronavirus disease 2019 (COVID-19).

12 Jan 2021

Hypoxia signaling pathway could lead to COVID-19 treatments

Researchers in Spain have demonstrated that studying the hypoxia signaling pathway could provide opportunities for treating coronavirus disease 2019 (COVID-19).

12 Jan 2021

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2

A recent study conducted at the University of Malta Medical School, Malta, has revealed that a drop in the level of particulate matter 2.5 (PM2.5), which are airborne pollutant particles with a diameter of 2.5 micrometer, in the atmosphere due to lockdown is associated with the arrival of a newer variant of SARS-CoV-2, which has eventually displaced the original virus after lockdown.

12 Jan 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

A snake venom enzyme shows anti-SARS-CoV-2 activity in vitro

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Influenza drug enisamium a potential COVID-19 treatment

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

How has the UK-derived SARS-CoV-2 mutant strain spread internationally?

Moderna to develop three new mRNA-based vaccines against HIV, influenza, and the Nipah virus

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

New N501 SARS-CoV-2 mutation may have been circulating in Italy since August 2020

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

Could fenofibrate be an effective antiviral against SARS-CoV-2?

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

Intranasal vaccination effectively reduces viral shedding of SARS-CoV-2 in monkeys

Structure of SARS-CoV-2 cytoplasmic tail uncovered

Effect of mutations in the South African SARS-CoV-2 variant on transmission and neutralization

Bleeding disorder linked to poor clinical outcomes in COVID-19 patients

Antigenic "supersite" could improve design of COVID-19 vaccines

Hypoxia signaling pathway could lead to COVID-19 treatments

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in